RxDoctor Payments Data

Kristy Chappell, MD

Family Medicine · Powderly, KYNPI 1073514030

Payments from drug & device makers

$6,435in general payments, 2019–2025

Across 465 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$941
  • Amgen$575
  • Pfizer$491
  • Lilly USA, LLC$476
  • AstraZeneca$242
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,435 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$17,465
Medicare patients
143
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide377$418,256
MounjaroTirzepatide237$279,764
JardianceEmpagliflozin274$193,628
EliquisApixaban234$162,138
VraylarCariprazine Hcl105$144,920
FarxigaDapagliflozin Propanediol187$129,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$84,293
XeljanzTofacitinib Citrate12$68,296
BenlystaBelimumab11$55,292
JanuviaSitagliptin Phosphate63$45,260
Nurtec OdtRimegepant Sulfate34$45,131
UbrelvyUbrogepant25$44,186
LinzessLinaclotide75$43,675
XareltoRivaroxaban51$42,314
Repatha SureclickEvolocumab56$42,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,123$443,205395 claims
Lilly USA, LLCMounjaro, Trulicity$476$311,301257 claims
PfizerEliquis, Xeljanz, Nurtec Odt$491$275,565280 claims
AbbVieVraylar, Ubrelvy, Linzess, Qulipta$941$246,422218 claims
Boehringer IngelheimJardiance, Combivent Respimat$194$209,294305 claims
GSKTrelegy Ellipta, Benlysta$84$139,584107 claims
AstraZenecaFarxiga$242$129,770187 claims
MerckJanuvia, Janumet$27$68,189100 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$42$23,84315 claims
AmgenProlia$575$22,54813 claims
Otsuka America Pharmaceutical, Inc.Rexulti$14$21,82918 claims
NovartisEntresto$43$18,65129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Powderly

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →